Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Realising Innovation in Transitions for Decarbonisation (REINVENT)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Theme: Fighting and adapting to climate change
Action type: Research and Innovation actions
Countries involved: Germany,Sweden,Netherlands,Netherlands,United Kingdom
Call: Pathways towards the decarbonisation and resilience of the European economy in the timeframe 2030-2050 and beyond (H2020-SC5-2016-OneStageB, 2016)
Start date: 2016-12-01
End date: 2020-11-30
Duration (months): 48.0
Total project cost (EUR): 4500000.0
EU funding (EUR): 4500000.0
Participants: 5
Project status: CLOSED

It is high time for the EU to develop pathways and strategies for decarbonisation also in emissions intensive sectors such as steel, plastics, paper, and meat and dairy. These are sectors where low carbon transitions are still relatively unexplored. Some progressive companies and other actors are just beginning to consider such pathways. The overall aim of REINVENT is to help Europe achieve its long-term climate objectives, while supporting the development of other societal benefits and the economy. A new evidence-based framework to assess the viability, challenges and governance implications of decarbonisation pathways will be developed and tools provided. It builds on the integration of conceptual work, empirical mapping and case-studies of innovations and climate initiatives, co-creation of knowledge and co-design of pathways, and careful assessment of the implications for other societal goals. The approach is to study and understand transitions and emerging initiatives from within sectoral contexts where government climate policy is only one of many factors that shape perceptions and strategies. As a result, REINVENT supports systemic innovation and system-wide transformation in the studied sectors. The project provides stakeholders with access to leading research and analytical capacity concerning key dimensions of low carbon transitions; it is also a platform for dialogue and learning about feasible pathways so that policies can be better aligned with the specific needs and conditions in different sectors. REINVENT will make an innovative scientific and societal contribution through (a) focusing on important economic sectors that are relatively unexplored yet important for the whole economy, (b) studying transitions from within these sectors, and (c) taking whole value chains into account through (d) a new analytical approach capable of advancing our understanding of key drivers, dynamics and implications of decarbonisation.

Keywords: decarbonisation pathways,resource efficiency
Cloud Computing via Homomorphic Encryption and Multilinear Maps (CLOUDMAP)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Computer science and informatics
Panel description: Informatics and information systems, computer science, scientific computing, intelligent systems
Countries involved: Luxembourg
Call: ERC Advanced Grant (ERC-2017-ADG, 2017)
Start date: 2018-10-01
End date: 2025-09-30
Duration (months): 84.0
Total project cost (EUR): 2491266.0
EU funding (EUR): 2491266.0
Participants: 1
Project status: SIGNED

The past thirty years have seen cryptography move from arcane to commonplace: Internet, mobile phones, banking system, etc. Homomorphic cryptography now offers the tantalizing goal of being able to process sensitive information in encrypted form, without needing to compromise on the privacy and security of the citizens and organizations that provide the input data. More recently, cryptographic multilinear maps have revolutionized cryptography with the emergence of indistinguishability obfuscation (iO), which in theory can been used to realize numerous advanced cryptographic functionalities that previously seemed beyond reach. However the security of multilinear maps is still poorly understood, and many iO schemes have been broken; moreover all constructions of iO are currently unpractical. The goal of the CLOUDMAP project is to make these advanced cryptographic tasks usable in practice, so that citizens do not have to compromise on the privacy and security of their input data. This goal can only be achieved by considering the mathematical foundations of these primitives, working "from first principles'', rather than focusing on premature optimizations. To achieve this goal, our first objective will be to better understand the security of the underlying primitives of multilinear maps and iO schemes. Our second objective will be to develop new approaches to significantly improve their efficiency. Our third objective will be to build applications of multilinear maps and iO that can be implemented in practice.

Keywords: fully homomorphic encryption,multilinear maps,obfuscation
Integrated energy solutions and new market mechanisms for an eXtended FLEXibility of the European grid (X-FLEX)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: A single, smart European electricity grid
Action type: Innovation actions
Countries involved: Austria,Austria,Spain,Cyprus,Slovenia,Bulgaria,Bulgaria,Greece,Greece,Slovenia
Call: Flexibility and retail market options for the distribution grid (H2020-LC-SC3-2019-ES-SCC, 2019)
Start date: 2019-10-01
End date: 2023-09-30
Duration (months): 48.0
Total project cost (EUR): 9463657.5
EU funding (EUR): 7314485.25
Participants: 13
Project status: SIGNED

The X-FLEX project proposes a set of integrated solutions that will facilitate the optimum combination of decentralised flexibility assets, of both on the generation (DER) and on the demand side (V2G, power-to-heat/cold, batteries, demand response) enabling all parties, including final prosumers, to offer their flexibility in the local and wholesale market creating benefits to all the actors in the smart grid value chain. This flexibility will make it possible to maintain a stable and secure electricity system with a growing role of variable renewable generation, yet resilient to extreme climate events. Up to now, the projects and research activities in this area have been focused mainly on specific energy sources and actors, considering only a very limited and isolated part of the distribution network, leaving aside all the opportunities existing throughout the flexibility offered by the energy value chain. In this context, X-FLEX will propose a new concept that will integrate and create synergies among all energy flexibility sources and technologies, promoting cooperation of all the actors of the smart grid and energy market, in an efficient and cost-effective manner. Through this holistic approach, X-FLEX aims to create the optimal combination of decentralised flexibility assets located along the whole energy value chain and new market mechanisms, providing benefits to all the actors of the smart grid and energy market, offering an all-win scenario. These X-FLEX project solutions will be tested in real conditions in 4 pilot sites in 3 EU Member states (Bulgaria, Slovenia and Greece), with different needs and socioeconomic and technological boundaries, involving multiple flexibility assets (batteries, power to heat/cold, vehicle to grid and other storage solutions) and all complementary actors of the energy network (DSO, TSO, microgrid operator, utilities, flexibility providers, local communities).

Keywords: battery,power to heat,power to cold,demand response,dres,holistic approach
The first process to synthesize Leather ‒ A fabric with the identical chemical composition and exact mechanical properties as leather (GELATEX)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Estonia
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-09-30
Duration (months): 3.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Leather is a highly sought-after product for its very specific look, touch, feel and durability properties. It is considered a premium material in the fashion, upholstery and automobile industries. The leather production market, with an estimated value of €100 billion is projected to grow by 6.2% to 2023. Sadly, the leather industry is one of the most polluting, due to the hide and skin tanning processes (excess water use, chemical spills, millions of CO2 emissions, worker health problems, skin diseases, filthy working conditions especially for women). Sustainability in leather production is a must in this day and age when eco-labels are sought after by brands to stand out from the crowd, as consumers demand higher quality standards. Currently, the one and only way to produce real leather is by taking the skin from an animal. Yes, alternatives like PVC and plant-based products exist, but their composition and properties are nowhere near that of real leather. Hence, they can never be adequate substitutes. At Gelatex, we have developed a cutting-edge new method of synthesizing layers of collagen, made from gelatin, creating a fabric of unprecedented quality, chemically equivalent to leather. Gelatex is the first to deliver this new animal-like leather without the need for tanning. The material is designed and configured following the industry requirements on tensile strength, resistance (to tear, to flexing, to puncture), good heat insulation, water vapor permeability and comfort. Ours is a scalable and efficient process allowing for Gelatex to be sold below the cost of current leather. We will can sell our tailor-made leather in colors thicknesses and sizes desired by our customers (manufacturers of leather articles). We thus expect to achieve revenues of €10 million in just 3 years. As our production facilities expand alongside a possible licensing model, our tech has the potential to generate €2 billion in revenue in only 10 years.
BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. (BIOXPLOR)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Ireland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-07-01
End date: 2019-11-30
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies). BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Keywords: software,clinical trials,life science,research,discovery,pharma,biotech,natural language processing,genomics,cloud
A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence (TIMELY)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: Research and Innovation actions
Countries involved: Austria,Germany,Germany,Germany,Spain,Germany,Germany,Spain,Greece,Greece,Netherlands,Netherlands
Call: Personalised early risk prediction, prevention and intervention based on Artificial Intelligence and Big Data technologies (H2020-SC1-DTH-2020-1, 2020)
Start date: 2021-01-01
End date: 2024-09-30
Duration (months): 45.0
Total project cost (EUR): 5737062.5
EU funding (EUR): 5737062.5
Participants: 17
Project status: SIGNED

Coronary artery disease (CAD) remains the leading cause of disease burden globally. CAD develops slowly, usually over decades, and depends on multiple (often modifiable) risk factors and their interactions. Self-management and patient activation are of rising importance as current restrictions in healthcare budgets impose great difficulties to enable the provision of qualitative secondary prevention to all cardiac patients in an era facing a huge cardiovascular disease epidemic. The main hypothesis in the patient-centered TIMELY pathway, is that a modular, collaborative eHealth platform, supported by Artificial Intelligence (AI) for the continuous and in-time prediction of cardiac risks and complications and the induction of targeted behavioural change interventions, can be effective and cost-efficient for the secondary prevention of CAD by limiting the physiological and psychological effects of the disease and improving risk factor and symptom management. Improvements in patients’ self-care and empowerment and clinicians’ efficiency are also expected. Along the continuum of the disease, prediction of the individual risk for disease progression, including physical impairment and severe events, is mandatory for timely intervention. TIMELY is a platform that provides AI-powered apps and dashboards and decision support tools assisting patients and clinicians to personalize healthcare based on risk evaluation, outcome prediction and tailored interventions. The platform will be developed based on a functional platform for Interoperability with electronic health records and security mechanisms, to ensure information completeness and continuity and to simplify data sharing. AI in TIMELY, built with big retrospective datasets of >23.000 CAD patients, will constantly monitor and evaluate risks and will indicate any deviation from defined therapy goals or unfavorable changes as well as propose proper interventions.

Keywords: preventive cardiology
The quest to understand interstellar sulfur and metal chemistry through synergetic laboratory and radio telescope observations (AstroSsearch)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-10-01
End date: 2023-09-30
Duration (months): 24.0
Total project cost (EUR): 172932.48
EU funding (EUR): 172932.48
Participants: 1
Project status: SIGNED

The fellowship AstroSsearch addresses open questions related to the abundance of sulfur and metals in the interstellar medium. While some species have been detected in astronomical environments, their abundance and complexity is quite low, thereby preventing a full understanding of the chemistry occurring in these environments. We will attack this problem with a synergic approach exploiting new laboratory microwave spectroscopy developments and radio astronomy observations. The key objectives include the generation of high-resolution rotational spectra of previously undetected sulfur/metal containing compounds and ions by mating broadband (chirped-pulse Fourier transform) microwave spectroscopy techniques with electrical discharge and laser ablation sources. Additionally, a novel discharge source will be developed in which the chemistry can be controlled to reveal likely reaction pathways that produce the observed species. This will allow for the postulation of viable astronomical formation mechanisms. The expected results are: (1) Development of a new controlled reactive chemistry source that can be paired with laser ablation. (2) High-resolution, rotational spectra of complex sulfur and metal containing species leading to their unambiguous identification in interstellar environments and their inclusion in theoretical models. (3) Elucidation of viable reaction pathways in astronomical environments for targeted and detected species and the insertion of these pathways into existing models. These results will facilitate radio astronomy detections, expanding our comprehension of astronomical chemistry. The synergy of laboratory spectroscopy and observational astrophysics will bring together all facets of the multidisciplinary field of astrochemistry, broadening our understanding of the chemistry that is occurring in interstellar and circumstellar environments and shedding light on the chemical complexity of the universe.

Keywords: astrochemistry,radio astronomical observations,laboratory astrophysics,interstellar molecules,sulfur and metal interstellar chemistry,broadband rotational spectroscopy,transient molecules
Transfer of multivirus-specific T-cells following transplantation (TRACE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Italy,Germany,Belgium,France,Netherlands,United Kingdom,United Kingdom
Call: New therapies for rare diseases (H2020-SC1-2017-Two-Stage-RTD, 2017)
Start date: 2018-01-01
End date: 2024-03-31
Duration (months): 75.0
Total project cost (EUR): 6000000.0
EU funding (EUR): 6000000.0
Participants: 11
Project status: SIGNED

Allogeneic stem cell transplantation (HSCT) is a curative treatment for a variety of diseases. Viral infections such as Cytomegalovirus (CMV), Epstein-Barr-virus (EBV) and Adenovirus (AdV) are major unsolved problems for patients receiving allogeneic HSCT. Refractory viral infections post-HSCT are rare, life-threatening conditions due to the deficient T-cell response post-SCT and lacking effective treatment options. Protective T-cell immunity could be restored by means of a procedure known as adoptive T-cell transfer. Although cellular immunotherapy is considered a major recent breakthrough in medicine, none of the cellular treatment approaches has yet become a standard treatment. The reason for this limited translation into daily clinical practice is the lack of controlled, prospective clinical trials investigating efficacy of immunotherapy. The objective of TRACE is to bring adoptive T-cell transfer into clinical routine as a life-saving, curative and safe treatment for refractory viral infection post-HSCT. TRACE is a multi-national clinical trial to prove efficacy and safety of adoptive T-cell transfer in immune-compromized individuals. For the first time, this trial will show that a unique individualized immunotherapy could be included into evidence based clinical routine in rare diseases. Regulatory and structural hurdles will be overcome by standardized GMP-procedures. It will be a major milestone in the development of medicine and health economics to bring such a unique personalized treatment approach into a clinical efficacy trial. The consortium provide excellence in immunotherapy through partners from basic, clinical and industrial research and GMP facilities, with proven qualification and expertise in the field of HSCT, GMP manufacturing and adoptive T-cell transfer. It will bring medicine towards physiological self-protection of the human body instead of cost-intensive toxic agents and will thereby improve survival and quality of life.

Keywords: immunotherapy,adoptive t cell transfer,viral disease in the immunocompromised host
MultiSensor sorting tools in a circular economy approach for the efficient recycling of PVB interlayer material in high-quality prodUcts from laminated glass coNstRuction and demolItion waStEs (SUNRISE)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Theme: Ensuring the sustainable supply of non-energy and non-agricultural raw materials
Action type: Innovation actions
Countries involved: Germany,Italy,Italy,Italy,Spain,Spain,Spain,Italy,Spain,Spain,Italy,Italy,Belgium,Greece,Belgium,Croatia,Lithuania,United Kingdom
Call: Raw materials innovation for the circular economy: sustainable processing, reuse, recycling and recovery schemes (H2020-LCCI-2020-EASME-twostage, 2020)
Start date: 2021-06-01
End date: 2024-11-30
Duration (months): 42.0
Total project cost (EUR): 9499371.25
EU funding (EUR): 8040302.51
Participants: 22
Project status: SIGNED

Laminated glass is obtained by bonding glass layers using a polymeric interlayer. Polyvinyl Butyral (PVB) is used as interlayer in laminated glass and their use in construction components is growing, therefore the end-of-life should be addressed. In EU, glass waste from Renovation and Demolition are quantified on 1.540.704 tons/year. The proper recycling of all building glass waste could avoid 925.000 tons of landfilled waste every year. Up to now, most of the post-consume PVB material in laminated glass is incinerated/landfilled, and only a 9 % is recycled in secondary uses. Recycling of PVB present several difficulties related with the contents of glass, humidity, mixing of compositions and polymer optical degradation which impede reusing as interlayer. SUNRISE will demonstrate within the current glass recycling business the application of an innovative optical multi-sensor sorting tool based on industrial in-line techniques (Raman, IRS, Fluorescence and Optical Spectroscopy) and AI algorithms which will allow optimal classification of laminated glass according to composition and degradation. Therefore, allowing the tailored mechano-chemical treatment for purification which will enable the post-consume PVB recycling and reusing as interlayer film. In order to ensure the success, the project counts with glass recycling associations and companies and main actors in mechano-chemical treatment of PVB and optical in-line systems. Industrials partners will validate the suitability of the final products in a market environment. Other transdisciplinary aspects will be incorporated including modelling, health, safety and environmental issues, dissemination & exploitation and standardisation. The success of SUNRISE will increase the European market in 360 million €/year by the proper collection and recycling of 1.250.352 tons/year of laminated glass, which will avoid PVB wastes of more than 125.000 tons, representing benefits at economic, environmental and social level.

Keywords: sorting,chemical,complex waste,recycling,laminated glass